Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Q4 2025 Annual earnings

Reported February 23, 2026 · After market close

Revenue$151.7MBeat by $7.1M
EPS-$0.20Miss by $0.10
Revenue estimate$144.6M
EPS estimate-$0.10

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$183.7M
EPS estimate-$1.43

Financials

Q4 2025

Income statement

See full
Revenue$151.7M+128%
Operating income-$8.0M+67.3%
Net income-$8.4M+63.8%
EPS (diluted)-$0.19+67.8%

Balance sheet

See full
Cash & equivalents$186.2M+91.2%
Total debt$83.0M+14.6%
Total equity$343.4M+53.0%
Total assets$562.2M+49.1%

Cash flow

See full
CapEx$6.4M+8,731%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.48B+64.2%
Enterprise value$3.37B+61.2%
P/S7.7×-3.9×

Profitability

See full
Operating margin-15.7%-6.8pp
Net margin-14.7%-6.4pp

Returns & leverage

See full
Return on equity-23.4%-8.5pp
Debt / equity0.2×-0.1×
Current ratio3.9×-0.6×

Segments

By segment

See full
Reportable Segment$151.7M+128%

FAQ

When did Tarsus Pharmaceuticals, Inc. report Q4 2025 earnings?
Tarsus Pharmaceuticals, Inc. (TARS) reported Q4 2025 earnings on February 23, 2026 after market close.
What were Tarsus Pharmaceuticals, Inc.'s Q4 2025 revenue and EPS?
Tarsus Pharmaceuticals, Inc. reported revenue of $151.7M and eps of $-0.20 for Q4 2025.
Did Tarsus Pharmaceuticals, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $144.6M by $7.1M. EPS missed the consensus estimate of $-0.10 by $0.10.
How did Tarsus Pharmaceuticals, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 128.4% from $66.4M a year earlier and eps grew 66.7% from $-0.60.
Where can I find Tarsus Pharmaceuticals, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001819790-26-000017) and the 10-K periodic report (0001819790-26-000019) directly on SEC EDGAR. The filing index links above go to sec.gov.